Voyager Therapeutics
75 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 910-509-3977
Website: http://www.voyagertherapeutics.com/
153 articles with Voyager Therapeutics
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
3/7/2023
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported fourth quarter and full year 2022 financial and operating results.
-
Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
-
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
3/6/2023
Voyager Therapeutics, Inc. today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from Voyager’s TRACER™ capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets.
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences - February 9, 2023
2/9/2023
Voyager Therapeutics, Inc. today announced that management will participate in the following investor conferences.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 24, 2023
1/24/2023
Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.
-
The neurodegenerative drug development space saw incremental victories in 2022. Leaders from Eisai, Voyager and QurAlis discuss upcoming milestones.
-
Neurocrine Biosciences and Voyager Therapeutics inked a CNS-targeted collaboration potentially worth a potential $4.4 billion.
-
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
1/9/2023
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases.
-
Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Voyager Therapeutics, Inc. today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.
-
Voyager's Al Sandrock, Alnylam's Yvonne Greenstreet and More Share Their Predictions for 2023
12/23/2022
BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series. -
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
12/14/2022
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 29, 2022
11/29/2022
Voyager Therapeutics, Inc. has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager.
-
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
11/8/2022
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.
-
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
11/1/2022
Voyager Therapeutics, Inc. today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 18, 2022
10/18/2022
Voyager Therapeutics, Inc. has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager.
-
Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.
-
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
10/4/2022
Voyager Therapeutics, Inc. today announced that Pfizer, Inc. (NYSE: PFE) has exercised its option to license a novel capsid generated from Voyager’s TRACERTM capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target.
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences - September 27, 2022
9/27/2022
Voyager Therapeutics, Inc., a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus capsids, announced that management will participate in the following investor conferences.
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022
9/22/2022
Voyager Therapeutics, Inc. has entered into employment agreements with Peter Pfreundschuh and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.